Quest Diagnostics : Management Change/Compensation - Form 8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K/A

Amendment No. 2

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 3, 2022

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation)

001-12215			16-1387862
(Commission File Number)			(I.R.S. Employer Identification No.)
500 Plaza Drive			07094
Secaucus,NJ
(Address of principal executive offices)			(Zip Code)
[phone]
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 Par Value	DGX	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

In its Current Report on Form 8-K dated February 3, 2022 (the "Original Report"), the Company reported the retirement of Stephen H. Rusckowski, the Company's current Chairman, Chief Executive Officer and President, and the appointment of James E. Davis as its next Chief Executive Officer and President, to be effective November 1, 2022. This Current Report on Form 8-K/A amends the Original Report to provide information about changes to Mr. Rusckowski's arrangements in connection with his retirement as Chief Executive Officer and President on November 1, 2022 and his service as Executive Chairman of the Company until March 31, 2023.

Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with his retirement, Mr. Rusckowski's existing employment agreement with the company will not be renewed, pursuant to notice given in accordance with the employment agreement on June 29, 2022. Mr. Rusckowski's compensation for his service as Executive Chairman will generally be aligned with his 2022 compensation.

Item 9.01. Financial Statements and Exhibits

d. Exhibit

104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

July 1, 2022

	QUEST DIAGNOSTICS INCORPORATED
	By:	/s/ William J. O'Shaughnessy, Jr.
		William J. O'Shaughnessy, Jr.
		Deputy General Counsel and Corporate Secretary